Compare EIC & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIC | NERV |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 210.1M |
| IPO Year | 2018 | 2014 |
| Metric | EIC | NERV |
|---|---|---|
| Price | $10.07 | $4.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $12.63 | $10.50 |
| AVG Volume (30 Days) | 90.0K | ★ 136.4K |
| Earning Date | 05-27-2026 | 05-01-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.17 | $1.93 |
| 52 Week High | $13.92 | $12.46 |
| Indicator | EIC | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 52.73 |
| Support Level | $9.83 | $3.81 |
| Resistance Level | $10.15 | $4.61 |
| Average True Range (ATR) | 0.14 | 0.35 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 78.13 | 65.79 |
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.